Schamroth L, Myburgh D P, Schamroth C L, Scholtz M E, Pincus D R, Kawalsky D L
Chest. 1985 Apr;87(4):448-51. doi: 10.1378/chest.87.4.448.
The efficacy of propafenone hydrochloride, a new antiarrhythmic agent, was evaluated in the treatment of chronic stable ventricular arrhythmias. Twenty-five patients who had suffered a myocardial infarction three months or longer before the trial were studied. All exhibited a minimum mean frequency of 30 ventricular ectopic beats per hour over at least two 24-hour Holter monitoring periods with the last recorded tape serving as a control. The mean decrease in ventricular ectopic activity with propafenone was 65.62 percent (p = less than 0.001). Side effects were infrequent, minimal, and of no clinical consequence. Oral propafenone was found to be an effective drug for reducing the level of chronic ventricular ectopy, as reflected by a short-term trial.
新型抗心律失常药物盐酸普罗帕酮治疗慢性稳定性室性心律失常的疗效进行了评估。研究了25例在试验前3个月或更长时间发生过心肌梗死的患者。所有患者在至少两个24小时动态心电图监测期内，每小时室性早搏的平均频率最低为30次，以最后记录的磁带作为对照。普罗帕酮使室性异位活动平均减少65.62%（p＜0.001）。副作用罕见、轻微，无临床意义。短期试验表明，口服普罗帕酮是一种降低慢性室性早搏水平的有效药物。
